<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT02316886</url>
  </required_header>
  <id_info>
    <org_study_id>AMCCV2014-13</org_study_id>
    <nct_id>NCT02316886</nct_id>
  </id_info>
  <brief_title>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Vulnerable Plaque</brief_title>
  <acronym>PREVENT</acronym>
  <official_title>The Preventive Coronary Intervention on Stenosis With Functionally Insignificant Stenosis With Vulnerable Plaque Characteristics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Seung-Jung Park</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>CardioVascular Research Foundation, Korea</agency>
      <agency_class>Other</agency_class>
    </collaborator>
  </sponsors>
  <source>Asan Medical Center</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to determine whether preventive coronary intervention on&#xD;
      functionally insignificant coronary stenosis with vulnerable plaque characteristics plus&#xD;
      optimal medical therapy reduces the incidence of the composite of cardiovascular death,&#xD;
      target vessel myocardial infarction, or ischemia driven target lesion revascularization&#xD;
      compared with optimal medical therapy alone.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Sub-analysis for each imaging test will be performed as below ;&#xD;
&#xD;
        -  NIRS(Near-infrared spectroscopy)&#xD;
&#xD;
        -  OCT(Optical coherence tomography)&#xD;
&#xD;
        -  VH-IVUS(IVUS-derived virtual histology)&#xD;
&#xD;
        -  IVUS(Intravascular ultrasonography)&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date type="Actual">October 5, 2015</start_date>
  <completion_date type="Anticipated">December 31, 2023</completion_date>
  <primary_completion_date type="Anticipated">September 30, 2023</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Target vessel failure</measure>
    <time_frame>2 years</time_frame>
    <description>Target vessel failure (TVF) is defined as a composite of cardiac death, target vessel related MI, ischemia-driven target vessel revascularization, or unplanned hospitalization for angina.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Major adverse cardiac event</measure>
    <time_frame>2 years</time_frame>
    <description>defined as cardiovascular death, nonfatal myocardial infarction, or unplanned rehospitalization due to unstable angina</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target lesion failure, defined as a composite of cardiovascular death, target lesion related myocardial infarction, or target lesion revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Death from any causes</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>The composite of death, myocardial infarction, and any repeat revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel-related myocardial infarction</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Target vessel revascularization</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>1 month</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>6 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>12 months</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Cardiac death and combinations of cardiac death with other components of MACE</measure>
    <time_frame>2 years</time_frame>
    <description>Cardiac death and combinations of cardiac death with other components of MACE at each time point</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Non-urgent revascularization procedures</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Unplanned hospitalization for angina</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>CCS(Canadian Cardiovascular Society) angina class</measure>
    <time_frame>2 years</time_frame>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>1 month</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>6 months</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>12 months</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Number of anti-anginal medication</measure>
    <time_frame>2 years</time_frame>
    <description>Number of anti-anginal medication at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>1 month</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>6 months</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>12 months</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Rate of non-urgent (repeat) revascularization</measure>
    <time_frame>2-year</time_frame>
    <description>Rate of non-urgent (repeat) revascularization at each point in time</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">1608</enrollment>
  <condition>Coronary Artery Disease</condition>
  <condition>Plaque, Atherosclerotic</condition>
  <arm_group>
    <arm_group_label>Coronary intervention</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Optimal Medical Treatment</description>
  </arm_group>
  <intervention>
    <intervention_type>Device</intervention_type>
    <intervention_name>Coronary intervention</intervention_name>
    <description>Bioresorbable Vascular Scaffold or Everolimus Eluting stent (EES) +Optimal Medical Treatment</description>
    <arm_group_label>Coronary intervention</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Optimal Medical treatment</intervention_name>
    <arm_group_label>Optimal Medical Treatment</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age 18 years or older&#xD;
&#xD;
          -  Symptomatic or asymptomatic coronary artery disease patients&#xD;
&#xD;
          -  Patients having at least one significant stenosis (diameter stenosis &gt; 50%) with FFR&#xD;
             &gt;0.80 and meeting two of the following:&#xD;
&#xD;
               1. MLA(minimal luminal area)&lt;4mm2&#xD;
&#xD;
               2. plaque burden&gt;70%&#xD;
&#xD;
               3. Lipid-rich plaque on NIRS(Intracoronary Near-Infrared Spectroscopy) (defined as&#xD;
                  maxLCBI4mm&gt;315)&#xD;
&#xD;
               4. TCFA(thin-cap fibroatheroma) defined by OCT(fibrous cap thickness&lt;65µm and&#xD;
                  arc&gt;90°) or VH-IVUS≥10% confluent NC with&gt;30° abutting to the lumen in 3&#xD;
                  consecutive slices)&#xD;
&#xD;
                    -  2 target vulnerable lesions&#xD;
&#xD;
          -  Eligible for percutaneous coronary intervention with Absorb Bioresorbable Vascular&#xD;
             Scaffold or Everolimus Eluting Stent&#xD;
&#xD;
          -  Willing and able to provide informed written consent&#xD;
&#xD;
          -  Reference vessel diameter 2.75-4.0&#xD;
&#xD;
          -  Lesion length ≤ 40&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Patients in whom the preferred treatment is CABG(Coronary artery bypass grafting)&#xD;
&#xD;
          -  Stented lesion&#xD;
&#xD;
          -  Bypass graft lesion&#xD;
&#xD;
          -  The patients who have more than or equal to 3 target lesions&#xD;
&#xD;
          -  2 target lesions in the same coronary territory&#xD;
&#xD;
          -  Heavily calcified or angulated lesion&#xD;
&#xD;
          -  Bifurcation lesion requiring 2 stenting technique&#xD;
&#xD;
          -  Contraindication to or planned discontinuation of dual antiplatelet therapy within 1&#xD;
             year&#xD;
&#xD;
          -  Life expectancy less than 2 years&#xD;
&#xD;
          -  Planned cardiac surgery or planned major non cardiac surgery&#xD;
&#xD;
          -  Woman who are breastfeeding, pregnant or planning to become pregnant during the course&#xD;
             of the study&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Gregg Stone, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Columbia University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Columbia University Medical Center</name>
      <address>
        <city>New York</city>
        <state>New York</state>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Kyoto University Hospital</name>
      <address>
        <city>Kyoto</city>
        <country>Japan</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Asan Medical Center</name>
      <address>
        <city>Seoul</city>
        <state>Songpa-gu</state>
        <zip>138-736</zip>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Hallym University Sacred Heart Hospital</name>
      <address>
        <city>Anyang</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gangwon National Univ. Hospital</name>
      <address>
        <city>Chuncheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Keimyung University Dongsan Medical Center</name>
      <address>
        <city>Daegu</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chungnam National University Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea, Daejeon ST. Mary's Hospital</name>
      <address>
        <city>Daejeon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Chonnam National University Hospital</name>
      <address>
        <city>Gwangju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Gachon University Gil Hospital</name>
      <address>
        <city>Incheon</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>ChonBuk National University Hospital</name>
      <address>
        <city>Jeonju</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Samsung Medical Center</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>The Catholic University of Korea Seoul St. Mary's Hospital</name>
      <address>
        <city>Seoul</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Bundang Cha Medical Center</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Seoul National University Bundang hospital</name>
      <address>
        <city>Sŏngnam</city>
        <country>Korea, Republic of</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>Christchurch Hospital and Canterbury DHB, University of Otago</name>
      <address>
        <city>Christchurch</city>
        <country>New Zealand</country>
      </address>
    </facility>
  </location>
  <location>
    <facility>
      <name>National Taiwan University Hospital</name>
      <address>
        <city>Taipei</city>
        <country>Taiwan</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>Japan</country>
    <country>Korea, Republic of</country>
    <country>New Zealand</country>
    <country>Taiwan</country>
    <country>United States</country>
  </location_countries>
  <removed_countries>
    <country>Australia</country>
    <country>China</country>
    <country>Italy</country>
    <country>Singapore</country>
  </removed_countries>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>December 1, 2014</study_first_submitted>
  <study_first_submitted_qc>December 11, 2014</study_first_submitted_qc>
  <study_first_posted type="Estimate">December 15, 2014</study_first_posted>
  <last_update_submitted>November 1, 2021</last_update_submitted>
  <last_update_submitted_qc>November 1, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 2, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Asan Medical Center</investigator_affiliation>
    <investigator_full_name>Seung-Jung Park</investigator_full_name>
    <investigator_title>MD,PhD</investigator_title>
  </responsible_party>
  <keyword>coronary intervention</keyword>
  <keyword>Vulnerable Plaque</keyword>
  <keyword>Insignificant Stenosis</keyword>
  <keyword>Bioresorbable Vascular Scaffold</keyword>
  <keyword>Everolimus Eluting stent</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
    <mesh_term>Constriction, Pathologic</mesh_term>
    <mesh_term>Plaque, Atherosclerotic</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

